QGEN — QIAGEN N.V.

NYSE · Health Care · Biotechnology · CIK 1015820 · Netherlands
Last close
$37.06
Market Cap
$7.64B
52W High
$42.33
52W Low
$32.53
ADV30
2,208,450
Next earnings
2026-08-04
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 492,320,000 309,603,000 116,626,000 68,043,000 5,782,065,000 646,289,000 2,450,359,000
Dec 2025 540,420,000 325,269,000 121,880,000 107,829,000 6,281,232,000 839,005,000 2,503,078,000
Sep 2025 532,583,000 331,259,000 137,293,000 130,043,000 6,553,497,000 1,355,594,000 2,904,082,000
Jun 2025 533,540,000 334,286,000 135,974,000 96,250,000 5,823,758,000 733,815,000 2,318,268,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$654,326,000
Investing CF
$-305,279,000
Financing CF
$-178,976,000
CapEx
$-207,126,000
Dividends Paid
$1,000
Buybacks
$0
EPS Diluted TTM
$2.04
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$2,748,390,000
Inventory
$301,888,000
Receivables
$520,033,000
ST Investments
$259,913,000
EBIT TTM
$523,521,000
Pretax Income TTM
$490,265,000
Interest Exp TTM
$33,256,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,098,862,976
EBITDA
$727,684,992
Free Cash Flow
$238,874,368
Enterprise Value
$8,664,398,848
Total Cash
$646,289,024
Total Debt
$1,667,063,040
Shares Out
206,250,000
Trailing EPS
$1.96
Book Value
$16.15
ROE
11.9%
ROA
6.0%
Div Yield
0.94%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,089,999,000 520,310,000 424,880,000 6,281,232,000 2,503,078,000 654,326,000
Dec 2024 1,978,214,000 199,899,000 83,591,000 5,689,622,000 2,122,283,000 673,551,000
Dec 2023 1,965,311,000 445,247,000 341,303,000 6,115,190,000 2,307,426,000 459,455,000
Dec 2022 2,141,518,000 576,228,000 423,211,000 6,287,735,000 2,821,124,000 715,264,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$2.64

Max Pain — expiry 2026-06-18

max pain strike: $35.00 · spot: $36.83 · call oi: 11,957 · put oi: 1,461
Expected Move to 2026-06-18: ±$2.32 (6.31%) — implied range $34.51$39.16 · ATM straddle on $35.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IBRX ImmunityBio, Inc. $7.44B $7.10
RGEN REPLIGEN CORP $7.37B $130.59
KYMR Kymera Therapeutics, Inc. $7.09B $86.21
HALO HALOZYME THERAPEUTICS, INC. $8.24B $69.50
TECH BIO-TECHNE Corp $8.45B $54.00

News headlines (Yahoo Finance, 1h cache)

QIAGEN Expands QIAcuity Gene Expression Portfolio to Drive dPCR Use
2026-06-15 15:16 · Yahoo
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma
2026-06-15 05:30 · Yahoo
Global Next Generation Sequencing Services Market Size/Share Worth USD 56.1 Billion by 2035 at a 23.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation,
2026-06-11 10:30 · Yahoo
Qiagen (QGEN) Up 12.1% Since Last Earnings Report: Can It Continue?
2026-06-05 15:30 · Yahoo
Agilent Technologies (A) Declined in Q1 Amid QIAGEN Acquisition Speculation
2026-06-03 13:51 · Yahoo
Evaluating Qiagen (QGEN) Valuation After Recent Short Term Share Price Recovery
2026-06-01 11:12 · Yahoo
Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?
2026-05-29 13:16 · Yahoo
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
2026-05-28 20:05 · Yahoo
QIAGEN Business Breakdown and Growth Drivers for 2026
2026-05-28 13:57 · Yahoo
[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate,
2026-05-21 17:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.